Some content on this site is not intended for people outside of the United States.
Virology & Infectious Diseases RFP Programs
and Topics of Interest
We offer both Request for Proposal (RFP) Programs and RFP Topics of Interest. An RFP Program specifically describes the research topic and may include detailed instructions on submitting a Letter of Interest (LOI) and full proposal. RFP Topics of Interest are brief descriptions of research topics that are of interest to the company. Both RFP types can be submitted through Gilead’s online proposal submission portal, Gilead OPTICS.
RFP Programs
| Program | Description | LOI Due Date |
|---|---|---|
| HIV Prevention - INCLUSION Global 2026 |
Implementation research of twice-yearly Lenacapavir to address unmet needs in HIV prevention | January 30, 2026 |
.
Gilead will evaluate all Letters of Interest (LOIs) received in Gilead OPTICS by June 30, 2026.
LOIs should address one or more of the following topic areas:
Safety and efficacy of AmBisome (liposomal amphotericin B*) alone or in combination with other antifungals
- AmBisome in patients with hematologic malignancies or disease
- AmBisome in critically ill patients in the intensive care unit (ICU)
- Characteristics of patients with breakthrough invasive fungal infections after antifungal prophylaxis and role of AmBisome as salvage treatment
- Nebulized AmBisome therapy – increased understanding of optimal dosing schedules**
- Intermittent AmBisome dosing strategies**
- AmBisome in empirical (early) treatment
Epidemiology of invasive fungal disease
- The role of AmBisome in light of changing epidemiology due to environmental changes and evolving resistance profiles – multi-country evaluation
*Researchers should consider the local label or indication as well as the availability of liposomal amphotericin B and contact their local Gilead medical representative for any questions.
**The use of AmBisome in this form or dosing schedule remains investigational, and its safety and efficacy have not been established by any regulatory authority.
Application Criteria
Gilead will evaluate all concepts received on a rolling basis until funds are exhausted. This TOI program is open to all geographies. The program will consider concepts which focus on the topics below:
Linkage to care and treatment of HCV+ pregnant patients through multi-specialty coordination:
- Studies which implement models of care supporting informed treatment initiation for HCV+ pregnant patients, including post-treatment follow up and post-partum outcomes